Toxicity Without Benefit With Paclitaxel Plus Everolimus Medscape December 12, 2011 (San Antonio, Texas) — It seemed like a good idea at the time, but including everolimus (Afinitor, Novartis) in a neoadjuvant chemotherapy regimen with paclitaxel (Taxol, Bristol-Myers Squibb) added nothing but toxicity to the ... |
